While ADCs represent a promising new type of therapy, the corresponding supply chain of monoclonal antibodies, payloads and linkers presents a significant challenge. This webinar will highlight the advantages when working with one source on your mAb, linker/ payload supplies and conjugation services. We will showcase the accelerators during the journey of the ADC to move from development to market faster. For example, how we manage to process the mAb from cell to clinic within 12 months. And address seamless process and analytical control strategies by integrating linker/payload and conjugation chemistry.
In this webinar you will learn:
● Advantages of a fully integrated supply chain
● How to accelerate mAb process development
● Process control strategies for ADC programs